Asset profile
Natrunix
Unknown / undisclosed
Evidence outlook · lead readout
NCT05363891 · Rheumatoid Arthritis
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05363891: The trial randomized 243 participants to Natrunix 200 mg, Natrunix 400 mg, or placebo, all with methotrexate, and masked participants, clinicians, investigators, and outcome assessors. Its primary clinical endpoint was ACR20 response at 12 weeks, but no results are available to determine whether the comparison was favorable.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
January 2027 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.